AI for Pharma 2026 Concludes Successfully: Empowering Drug Discovery with AI, One Step Further
The AI for Pharma Biopharmaceutical AI Summit was held from 2026 to 7, 8/6.，Deeply integrate with 2026BPD Shanghai.
The two-day agenda sends a clear signal:AI in biopharmaceuticals has moved beyond the "proof-of-concept" stage.Industry focus has shifted from "Can AI do it?" to "How can AI deliver quantifiable business value?"
During AI for Pharma20+ AI drug discovery case studiesCentralized public sharing across key stages—from target discovery and molecule generation/optimization to process development and quality control—leveraging real-world business scenarios to validate AI's commercial value through quantifiable efficiency gains and cost optimization.
40 remaining C-level executives from top domestic and international pharmaceutical companies and AI technology firmsReach consensus on strategic priorities including AI R&D ROI, data governance and compliance, and organizational capability building. Breaking down data silos, establishing industry standards, and cultivating multidisciplinary talent are key drivers for scaling AI-driven drug discovery.
AI for Pharma 2026 Biopharma AI SummitDrive the AI ecosystem from "sporadic engagement" to "systematic co-creation," marking the next chapter of transformation in China's biopharmaceutical industry—from "imaginable" to "actionable."
Forum Highlights
AI in CMC & Intelligent Manufacturing
AI for Science
